TEL AVIV, Israel - Nov. 5, 2019 - VALFIX Medical Ltd. is pleased to announce the issuance of US Patent No. 10,463,486 issued November 5th, 2019. This is the second US patent granted for VALFIX and was approved only 2 years and 9 months since its priority date. This new patent provides an additional layer of protection for VALFIX's trans-catheter repair and replacement technology and is part of VALFIX's current patent portfolio, which includes U.S. patent No. 10,278,820 issued on May 7, 2019, and additional patents pending.
VALFIX Medical is developing the first complete trans-catheter solution that combines repair and replacement treatments for Heart-Failure patients suffering from severe Mitral Regurgitation (MR); offering a viable alternative to open-heart surgery.
"We continue to protect, improve and advance our technology as planned. The issuance of this second patent continues to validate the uniqueness of our technology and its level of innovation," states Eli Bar, CEO & Founder of VALFIX Medical Ltd. "It is an exciting time for our company as market needs remain large and open for new and innovative solutions to improve quality of life and save lives for Heart-Failure patients suffering from severe MR."
VALFIX Medical's technology is distinguished in its approach to offer both repair and replacement treatment in one procedure; emulating the "best-in-class" surgical technique for severe Mitral Regurgitation to alleviate heart failure symptoms, improve quality of life, and save lives.
VALFIX Medical continues to develop its patent portfolio with other patents in preparation and pending.
About VALFIX Medical:
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Devra Igra email@example.com +972 73 374 4805